Celgene Reports Update on its Collaboration with Jounce Therapeutics

 Celgene Reports Update on its Collaboration with Jounce Therapeutics

Celgene Reports Update on its Collaboration with Jounce Therapeutics

Shots:

  • Jounce to receive $50M up front, $180M as development & regulatory milestones, $300M as commercial milestones, royalties on global sales and will retain WW rights to its pipeline including vopratelimab, JTX-4014 and all discovery programs
  • Celgene to get WW rights to develop & commercialize Jounce’s JTX-8064, an anti-leukocyte immunoglobulin like receptor B2 (LILRB2) Ab, focuses on tumor-associated macrophages. Additionally, Celgene signed a mutual agreement with Jounce to terminate its 2016 deal which focuses on the development of immuno-oncology therapies
  • Jounce’s vopratelimab is a mAb JTX-4014 targeting ICOS, a protein present on the surface of T-cells found in solid tumors, assessed in ICONIC P-I/II study. JTX-4014 is an IgG4 mAb designed to block binding to PD-L1 and PD-L2 being evaluated in P-I study

Click here to­ read full press release/ article | Ref: GlobeNewsWire | Image: The Street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post